C
Indications (Calamus) — Adenopathy (f; WO2); Ague (f; CRC; KAB); Angina (f; PHR);
Anorexia (f; APA; CAN; CRC; KAB; PHR); Anxiety (1; IJP29:S340); Arthrosis (f; APA); Asthma
(f; VVG); Bacteria (1; CRC; MPI); Bronchosis (f; CRC; SUW); Bubo (f; CRC); Cancer (f; JLH);
Cancer, abdomen (f; JLH); Cancer, colon (f; JLH); Cancer, liver (f; JLH); Cancer, rectum (f;
JLH); Cancer, spleen (f; JLH); Cancer, stomach (f; JLH); Cancer, testis (f; JLH); Cancer, uterus
(f; JLH); Cancer, vagina (f; JLH); Carbuncle (f; CRC); Catarrh (f; WO2); Cholera (f; MIC);
Colic (f; APA; CAN; CRC; KAP; MIC; SUW); Conjunctivosis (f; CRC); Constipation (f; KAP);
Cough (f; KAB; MIC); Cramp (1; APA; CAN; MIC; SUW; VVG); Cystosis (f; CRC); Deafness
(f; CRC); Diarrhea (f; SUW; VVG); Dysentery (f; CRC; KAB; VVG); Dyspepsia (1; APA; CAN;
SUW; ZUL); Enterosis (f; CAN); Epilepsy (f; APA; KAP; WO2); Fever (1; APA; CAN; CRC;
EFS; WO2); Fungus (1; WO2); Gangrene (f; JLH); Gas (1; APA; CAN; CRC; SUW; VVG);
Gastrosis (f; CAN; MIC; PHR); Gingivosis (f; PHR); Gout (f; CRC); Headache (f; CRC);
Hepatosis (f; JLH); High Blood Pressure (1; APA; WO2; ZUL); Incontinence (f; CRC); Induration
(f; JLH); Infection (1; CRC; EFS; FNF); Insomnia (1; APA; PHR); Lice (1; WO2); Lumbago
(f; CRC); Malaria (f; CRC; SUW); Melancholy (f; CRC); Mycosis (1; WO2); Nervousness (1;
APA; MPI; PHR; WO2; ZUL); Neurasthenia (f; CRC); Nicotinism (f; APA); Ophthalmia (f;
CRC); Orchosis (f; JLH); Pain (1; KAP; ZUL); Paralysis (f; KAP); Respirosis (f; ZUL); Rheu-
matism (f; APA; CRC; KAP); Rickets (f; CRC); Scirrhus (f; JLH); Scrofula (f; CRC); Snakebite
(f; SUW); Sore (f; JLH); Sore Throat (f; KAB); Splenosis (f; JLH); Stomachache (f; APA; MIC);
Swelling (f; KAP); Teething (f; APA); Tuberculosis (1; MPI); Tumor (f; JLH); Typhoid (f; CRC);
Ulcer (f; CAN; PHR); Uterosis (f; JLH); Vaginosis (f; JLH); Varicosis (f; APA); Vertigo (f; CRC);
Water Retention (f; EFS; KAP).Dosage (Calamus) — 2–7 g powdered root (10–15 as emetic) (KAP).Contraindications, Interactions, and Side Effects (Calamus) — Class 1, only for the asarone-
free diploid rhizome. Class 2b for the triploid and tetraploid (AHP). CAN reports that the beta-
asarone in the oil is carcinogenic and nephrotoxic, and may cause convulsions. AHP hints that
the risks, like those of safrole, may not be as serious as the press would have us believe. Oil
carcinogenic, convulsant; kidney damage and tremors. May potentiate MAOI therapy (CAN).
And a real bombshell for uncut aromatherapists, “In general, the topical application of any
undiluted EO is not recommend” (CAN). EO LD50 = 777 orl rat; LD50 = 221 ipr rat (CAN);
LD50 = >5000 der guinea pig (CAN).